Hoth Therapeutics Awarded U.S. Patent for Cancer-Fighting HT-KIT Oncology Platform

Allowed Claims Cover Composition-of-Matter and Methods Targeting MS4A6A Pre-mRNA Splicing to Reduce Surface Expression of the High-Affinity IgE Receptor (FcεRI); Strengthens Intellectual Property Foundation Underlying the HT-KIT Mast Cell Program HOBOKEN, N.J., May 26, 2026 /PRNewswire/...